David Khayat – författare

David Khayat led France’s war against cancer and has been in the medical trenches for thirty years. In this international bestseller, he shares his knowledge on the role of diet and lifestyle in getting different types of cancer and how to bolster the body against those risks. Bringing together his own cross-national studies with those of other top cancer experts, Khayat empowers readers with the latest nutritional knowledge. He guides them through all food groups, including supplements and beverages, often supplying surprising advice. Men and women of all ages will find tips to meet their specific needs in this accessible, user-friendly guide. Handy charts at the end of the book distill information on the best—and worst—foods, habits and cooking methods for every body.

Virtual endoscopy progressively enters the real world The development of virtual reality is one of the most striking features of our Western societies. Beside chil­ dren games and movies, its scope has expanded to medical imaging through 3D CT scan surface or volume re­ constructions. Whatever the site clinicians are able to perform real endoscopy (RE), radiologists can now also provide virtual endoscopy (VE) images. VE enters our medical practice. The next question is to weigh the pros and cons. VE has the unique advantage to offer high-quality images obtained through a noninvasive and well-tolera­ ted procedure performed in outpatients. Compared to RE, it carries no risk of bleeding, perforation or trans­ mission of viruses. Importantly, VE can pass high-grade stenoses affecting large bowel, urinary tract or tra­ cheobronchial tree, and visualize areas hard to visit by optic fibers such as intracranial regions. 3D VE images can be commented with patients, and this might reduce potential misunderstanding and its medico-legal consequences. Last but not least, VE is the sole alternative offered both to those who refuse RE, and to severely ill elderly patients. Then, should we consider VE as the Deus ex machina of modem medical imaging - with CT scan as rna­ china - ? Clearly, the answer is no, given VE knows severals limits and pitfalls. One of the most important me­ rits of this book is to discuss honestly these aspects. First, VE will never allow to perform biopsies or resections.

This is the third volume of our series Progress in Anti-Cancer Chemo­ therapy. Following the strategy of the first two volumes, it covers selected aspects of progress in this fast moving field of Oncology, with contribu­ tions from some of the world's best known leaders in both basic and clin­ ical research. This year we focused on seven areas: Three prominent Clinical investigators reviewed conceptual advances in cancer research. Dr Buzdar presented a history and overview of the protection of human subjects who participate in clinical research, and the mechanisms developed to assure the ethical conduct of research on human beings. Frei reviewed an exciting and rapidly moving area of che­ motherapy of solid tumors, including a cogent discussion of the issues related to dose-intensification. Fisher summarized conceptual advances in our therapeutic approach to breast cancer and the paradigm shifts that lead us to our current management strategies. From this summary he pro­ jected breast cancer research into the future, a daunting task under any circumstance. Fundamental research in cancer biology has been responsible for our improved understanding of the development and progession of malignant disease. Such understanding will lead to improved diagnosis, therapy, and eventually, prevention. Isaacs reviews the area of hereditary breast cancer, a topic undergoing rapid transformation and with mUltiple impli­ cations in the daily practice of medicine. Fidler, an international expert in metastasis research reviews the potential utility of angiogenesis inhib­ itors in research and the therapeutic ramifications.

This is the fourth volume of the series Progress in Anti-Cancer Therapy. This volume mainly covers: five types of cancer (breast, prostate, bladder, lymphoma and ovarian), the role of HIV and HTLV in cancer, and some developmental pharmacology and behavioral issues. It particularly focuses on one of the most common cancers: prostate cancer. Other covered points are: review of all trials reported in order to update our practices in bladder cancer; description of new drugs which should be integrated in the treatment of metastatic breast cancer, a summary of conceptual advances on our therapeutic approach to none-metastatic breast cancer; excellent review of the current knowledge and perspectives on the treatment of ovarian cancer; description of the state of the art regarding the use of sentinel node biopsy in melanoma patients and on the same hand an exhaustive overview on the emerging new drugs for the treatment of human lymphomas.

Une cuisine gourmande, savoureuse et anticancer, tel est le projet du nouveau livre du professeur David Khayat. Bien manger pour mettre toutes les chances de votre côté et limiter le risque de cancer. Vous découvrirez avec ce livre qu’il est possible de faire bon pour le goût et bon pour la santé en même temps ! Cécile Khayat, jeune pâtissière et passionnée de cuisine, a imaginé pour vous de délicieuses recettes à partir d’aliments sélectionnés tant pour leur goût et leurs bienfaits que pour leurs propriétés anticancer. Vous trouverez des recettes inventives, conviviales et faciles à réaliser, en peu de temps, par chacun d’entre nous. Manger sain devient un véritable plaisir ! 120 recettes, 60 produits, pour cuisiner sain tout en conservant le goût des bonnes choses. Un livre de recettes anticancer tout à fait nouveau. Le professeur David Khayat est chef de service de cancérologie à l’hôpital de la Pitié-Salpêtrière et enseigne à l’université Pierre-et-Marie-Curie. Il a notamment publié de grands succès de librairie : Les Chemins de l’espoir, Le Vrai Régime anticancer, Les Recettes gourmandes du vrai régime anticancer, De larmes et de sang, Prévenir le cancer, ça dépend aussi de vous. Cécile Khayat, jeune chef pâtissière et cuisinière, a notamment travaillé chez Pierre Hermé. Elle a créé et réalisé toutes les recettes de ce livre. Nathalie Hutter-Lardeau apporte son expertise de spécialiste en nutrition sur les produits présentés dans ce livre.

« Je voudrais, dans ce livre, vous transmettre tout ce que je sais, tout ce que j’ai vu, observé pendant mes trente-cinq ans de lutte contre le cancer, pour vous aider le plus possible en amont à vous prémunir de cette maladie et, peut-être, à l’éviter. Il y a un certain nombre de comportements qu’il faut changer, d’autres qu’il faut favoriser, un certain nombre de produits dont il vaudrait mieux se garder et un certain nombre d’aliments qu’il est bénéfique de privilégier. Vous pouvez faire chaque jour, dans votre vie quotidienne, des petits choix et des petits gestes qui, ajoutés les uns aux autres, peuvent produire des effets positifs sur votre santé. Je vous livre ici tous mes meilleurs conseils, simples, pratiques et concrets, qui peuvent aider à diminuer le risque de développer un cancer, ou tout simplement à en retarder l’apparition : des recommandations toutes nouvelles, contraires aux idées reçues. Prévenir, c’est cela, agir en amont, et ça dépend de chacun d’entre nous. » Pr David Khayat. Des conseils, simples, pratiques et concrets. Des préconisations qui renouvellent vraiment la prévention du cancer. Un livre indispensable. David Khayat est chef de service de cancérologie à l’hôpital de la Pitié-Salpêtrière et professeur à l’université Pierre-et-Marie-Curie. Il a notamment publié de grands succès de librairie : Les Chemins de l’espoir, Le Vrai Régime anticancer, Les Recettes gourmandes du vrai régime anticancer et De larmes et de sang.

« Je vous livre ici tout ce à quoi je tiens, tout ce à quoi je crois, tout ce qui fait de moi ce que je suis à ce moment particulier de ma vie. Je voudrais que vous entriez dans la peau du médecin pour mieux comprendre la relation au patient. C’est en face de lui que je m’assois. Je suis face à face avec un être humain qui souffre, que j’écoute, que je cherche à guérir et à comprendre. Guérir le corps est sans nul doute fondamental, mais veiller à ne pas blesser l’âme est tout aussi important. C’est cela, selon moi, être médecin. C’est la raison pour laquelle j’ai écrit ce livre. Je vous propose une vraie rencontre avec le médecin que je suis. Je mets ma pratique à nu, je la décris dans le détail et au scalpel. Je ressens aussi le besoin de parler de ma propre attitude face à la mort, face à la peur. » Le professeur David Khayat est chef de service de cancérologie à l’hôpital de la Pitié-Salpêtrière et professeur à l’université Pierre-et-Marie-Curie. Il a notamment publié Les Chemins de l’espoir et Le Vrai Régime anticancer, qui sont de grands succès de librairie.

L’annonce d’un cancer est toujours un très gros choc. Et pourtant, beaucoup de cancers guérissent. Encore faut-il réussir son parcours du début de la maladie jusqu’au moment de retrouver une vie normale. Comprendre la maladie, choisir son lieu de soins, établir un partenariat avec son médecin sont les premières étapes. Il faut aussi prendre en compte l’impact psychologique et physique de la maladie, effectuer les bonnes démarches et connaître ses droits. Tout un parcours qu’il faut réaliser dans les meilleures conditions. Ce guide vous oriente, vous informe et vous accompagne dans votre cheminement personnel, médical et administratif.• À chaque étape de la maladie, il aide à s’informer, s’orienter, se guider : puis-je demander un deuxième avis ? Vais-je guérir ? Comment choisir mon lieu de soins ?• Des définitions claires et précises des traitements : certains sont-ils meilleurs que d’autres ? Quand consulter en urgence ? Est-ce mon intérêt de participer à un essai clinique ?• 100 questions réponses sur vos rapports avec l’hôpital, votre employeur, la Sécurité sociale, les aides à domicile, les assurances. Aurai-je des frais à débourser ? Vais-je pouvoir emprunter ? Un document précieux pour vous et votre famille. David Khayat est professeur à l’université Pierre-et-Marie-Curie. Il est chef de service de cancérologie à l’hôpital de La Pitié-Salpêtrière. Il a notamment publié Les Chemins de l’espoir. Odilon Wenger est journaliste, spécialisé dans l’économie de la santé. Dominique Delfieu, médecin généraliste, anime le réseau MG Cancer à Paris.

" Les progrès accomplis dans la recherche contre le cancer, les avancées thérapeutiques sont devenus tels qu’ils ouvrent devant nous, sans aucun doute permis, de merveilleux chemins vers l’espoir. Ce sont ces chemins que je vous propose de découvrir ensemble. " David Khayat David Khayat est professeur à l’université Pierre-et-Marie-Curie. Il est chef de service de cancérologie à l’hôpital de La Pitié-Salpêtrière. Conseiller permanent de la Mission interministérielle pour la lutte contre le cancer, il est l’un des responsables de la mise en œuvre de l’un des grands chantiers présidentiels du quinquennat.

« Ce livre est la somme de trente années de recherche en cancérologie. Pendant toutes ces années, quels qu’aient été mon titre, mon rang ou ma responsabilité, le fil conducteur de ma vie a toujours été le soin aux malades atteints du cancer. Dans un combat, malade par malade, face à tous les cancers, innombrables, mystérieux, l’un après l’autre, un peu comme un soldat qui se battrait à l’arme blanche, j’ai essayé d’amener mes patients à la victoire. À la guérison. Combien ces combats ont été durs ! Combien les souffrances pour eux ont été grandes ! Mais voilà, le bilan reste tragique. À cette étape de ma vie, je me dois de constater que quelque chose aurait dû être fait depuis longtemps. Ou, en tout cas, développé davantage : la prévention. C’est pourquoi j’ai voulu écrire ce livre pour qu’ensemble nous puissions réellement parler d’espoir et nous dire qu’un jour peut-être nos enfants vivront dans un monde débarrassé à tout jamais de la menace de ce fléau. Or la vérité est là : ce sont nos comportements alimentaires, pris au sens large, qui sont responsables de bon nombre de cancers. Aujourd’hui, je voudrais présenter le vrai régime anticancer. En suivant mes conseils, vous pourrez lutter de la façon la plus efficace pour essayer de réduire le risque de cancer. C’est l’objectif de ce livre. »Pr David KhayatDavid Khayat est chef de service de cancérologie à l’hôpital de la Pitié-Salpêtrière et professeur à l’université Pierre-et-Marie-Curie. Il a notamment publié Les Chemins de l’espoir et Le Guide pratique du cancer.

Virtual endoscopy progressively enters the real world The development of virtual reality is one of the most striking features of our Western societies. Beside chil­ dren games and movies, its scope has expanded to medical imaging through 3D CT scan surface or volume re­ constructions. Whatever the site clinicians are able to perform real endoscopy (RE), radiologists can now also provide virtual endoscopy (VE) images. VE enters our medical practice. The next question is to weigh the pros and cons. VE has the unique advantage to offer high-quality images obtained through a noninvasive and well-tolera­ ted procedure performed in outpatients. Compared to RE, it carries no risk of bleeding, perforation or trans­ mission of viruses. Importantly, VE can pass high-grade stenoses affecting large bowel, urinary tract or tra­ cheobronchial tree, and visualize areas hard to visit by optic fibers such as intracranial regions. 3D VE images can be commented with patients, and this might reduce potential misunderstanding and its medico-legal consequences. Last but not least, VE is the sole alternative offered both to those who refuse RE, and to severely ill elderly patients. Then, should we consider VE as the Deus ex machina of modem medical imaging - with CT scan as rna­ china - ? Clearly, the answer is no, given VE knows severals limits and pitfalls. One of the most important me­ rits of this book is to discuss honestly these aspects. First, VE will never allow to perform biopsies or resections.

This book includes some selected presentations given at the 3rd International Congress on Neo-Adjuvant Chemotherapy which was held in Paris from February 6th to February 9th, 1991. It was attended by over 2000 physicians from around the world and by 700 nurses. Its organisation was saddened by the untimely death of Professor Claude Jacquillat on October 12th, 1990. It was further complicated in January and February 1991 by the gulf events which led some guests to cancel their participation. However with the outstanding help of the two presidents cho­ sen by Claude Jacquillat before his death, Pierre Banzet from Paris and James F. Holland from New York, the organizers could set up an exciting meeting confirming the impact of neo-adjuvant chemotherapy on relatively new indi­ cations such as non-small lung cancers, bladder cancer, esophagal cancer, cer­ vix cancer, etc ... It is noteworthy that a contradictory debate on primary chemotherapy in non-small lung cancer turned into a consensus conference. In breast cancer, the downstaging induced by primary chemotherapy is ack­ nowledged by all and the conviction that Jacquillat defended so heartily that breast preservation should be proposed to all patients with breast cancer what­ ever their tumour size is shared now by more and more people. A special emphasis was given to new drugs, new combination, new access (locoregional therapy) and new developments such as that of growth factors and of interleukin 2.

This book includes some selected presentations given at the 3rd International Congress on Neo-Adjuvant Chemotherapy which was held in Paris from February 6th to February 9th, 1991. It was attended by over 2000 physicians from around the world and by 700 nurses. Its organisation was saddened by the untimely death of Professor Claude Jacquillat on October 12th, 1990. It was further complicated in January and February 1991 by the gulf events which led some guests to cancel their participation. However with the outstanding help of the two presidents cho­ sen by Claude Jacquillat before his death, Pierre Banzet from Paris and James F. Holland from New York, the organizers could set up an exciting meeting confirming the impact of neo-adjuvant chemotherapy on relatively new indi­ cations such as non-small lung cancers, bladder cancer, esophagal cancer, cer­ vix cancer, etc ... It is noteworthy that a contradictory debate on primary chemotherapy in non-small lung cancer turned into a consensus conference. In breast cancer, the downstaging induced by primary chemotherapy is ack­ nowledged by all and the conviction that Jacquillat defended so heartily that breast preservation should be proposed to all patients with breast cancer what­ ever their tumour size is shared now by more and more people. A special emphasis was given to new drugs, new combination, new access (locoregional therapy) and new developments such as that of growth factors and of interleukin 2.

This is the third volume of our series Progress in Anti-Cancer Chemo­ therapy. Following the strategy of the first two volumes, it covers selected aspects of progress in this fast moving field of Oncology, with contribu­ tions from some of the world''s best known leaders in both basic and clin­ ical research. This year we focused on seven areas: Three prominent Clinical investigators reviewed conceptual advances in cancer research. Dr Buzdar presented a history and overview of the protection of human subjects who participate in clinical research, and the mechanisms developed to assure the ethical conduct of research on human beings. Frei reviewed an exciting and rapidly moving area of che­ motherapy of solid tumors, including a cogent discussion of the issues related to dose-intensification. Fisher summarized conceptual advances in our therapeutic approach to breast cancer and the paradigm shifts that lead us to our current management strategies. From this summary he pro­ jected breast cancer research into the future, a daunting task under any circumstance. Fundamental research in cancer biology has been responsible for our improved understanding of the development and progession of malignant disease. Such understanding will lead to improved diagnosis, therapy, and eventually, prevention. Isaacs reviews the area of hereditary breast cancer, a topic undergoing rapid transformation and with mUltiple impli­ cations in the daily practice of medicine. Fidler, an international expert in metastasis research reviews the potential utility of angiogenesis inhib­ itors in research and the therapeutic ramifications.

This is the fourth volume of our series Progress in Anti-cancer Therapy. For the past four years we have taken the challenge to select each year, some of the most interesting topics on the wide field of oncology. As usual, this volume continues the tradition and covers five cancers (breast, prostate, bladder, lym­ phoma and ovarian), the role of HIV and HTLV in cancer, as well as some deve­ lopmental pharmacology and behavioral issues. This year, we have particularly focused our attention on one of the most com­ mon (although rarely addressed) cancer accounting for more than 315,00 newly diagnosed cases and 41,000 cancer-related deaths annually (Landis SH et al., 1999) : prostate cancer. Five chapters address some of the issues concerning this disease. The chap­ ter by Schroder describes the hopes and pitfalls of early detection of prostate cancer. It reviews the literature on screening studies that have been performed both in the US and in Europe. These studies suggest that cancer mortality could be reduced by screening for prostate cancer, mostly through PSA testing. However, the effectiveness of early detection still needs to be definitely confir­ med and ongoing randomized studies are described, the results of which will probably help the medical community determine the worth of PSA-based scree­ ning for prostate cancer. On the same hand, the paper from von Eschenbach is reviewing the clinical problems that are related this disease.

Imaging techniques are often called upon in oncology in virtue of their essential role in tumor diagnosis, extension work up to various organs and detection of relapse. They are also indispensable in research and in clinical practice, allowing an objective assessment of tumoral regression in patients undergoing treatment. It is currently impossible to establish the management plan of a cancer patient or to obtain follow-up of such a patient under treatment without clinical and imaging confrontation.